Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis

BACKGROUND: Efficacy trials showed that glucagon-like peptide–1 receptor (GLP1R) agonists reduced metabolic risk factors in addition to glucose lowering, but the cardiovascular and microvascular efficacy of this drug class remains to be determined. We aimed to evaluate the overall cardiovascular and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaowen, Shao, Fei, Zhu, Lin, Ze, Yuyang, Zhu, Dalong, Bi, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142638/
https://www.ncbi.nlm.nih.gov/pubmed/30223891
http://dx.doi.org/10.1186/s40360-018-0246-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142638/
https://www.ncbi.nlm.nih.gov/pubmed/30223891
http://dx.doi.org/10.1186/s40360-018-0246-x

Ejemplares similares